D3- vitamin omdannes til 25- hydroxyvitamin D3 i leveren og lagres indtil der er brug for det.
http://www.emea.europa.eu/

Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver, and stored until needed.
http://www.emea.europa.eu/

D3- vitamin fordeles hurtigt til hovedsageligt leveren, hvor det metaboliseres til 25- hydroxyvitamin D3, den væsentligste oplagringsform.
http://www.emea.europa.eu/

Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3, the major storage form.
http://www.emea.europa.eu/

Biotransformation D3- vitamin metaboliseres hurtigt ved hydroxylering i leveren til 25- hydroxyvitamin D3 og metaboliseres efterfølgende i nyrerne til 1, 25- dihydroxyvitamin D3, som repræsenterer den biologisk aktive form.
http://www.emea.europa.eu/

Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3, and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3, which represents the biologically active form.
http://www.emea.europa.eu/

17 vitaminmangel (serum 25- hydroxyvitamin D ≤22, 5 nmol/ l [≤9 ng/ ml]) var signifikant reduceret med 92% med ADROVANCE (70 mg/ 2800 IE) versus alendronat alene (henholdsvis 1% versus 13%).
http://www.emea.europa.eu/

The percentage of patients with vitamin D deficiency (serum 25- hydroxyvitamin D <  22.5 nmol/ l [<  9 ng/ ml]) was significantly reduced by 92% with ADROVANCE (70 mg/ 2800 IU) vs. alendronate-only (1% vs 13%, respectively).
http://www.emea.europa.eu/

Procentdelen af patienter med D- vitaminmangel (serum 25- hydroxyvitamin D < 22, 5 nmol/ l [< 9 ng/ ml]) var signifikant reduceret med 92% med FOSAVANCE (70 mg/ 2800 IE) versus alendronat alene (henholdsvis 1% versus 13%).
http://www.emea.europa.eu/

The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D <  22.5 nmol/ l [<  9 ng/ ml]) was significantly reduced by 92% with FOSAVANCE (70 mg/ 2800 IU) vs. alendronate-only (1% vs 13%, respectively).
http://www.emea.europa.eu/

Procentdelen af patienter med D - vitaminmangel (serum 25- hydroxyvitamin D ≤ 22, 5 nmol/ l [≤9 ng/ ml]) var signifikant reduceret med 92% med FOSAVANCE (70 mg/ 2800 IE) versus alendronat alene (henholdsvis 1% versus 13%).
http://www.emea.europa.eu/

The percentage of patients with vitamin D deficiency (serum 25- hydroxyvitamin D <  22.5 nmol/ l [<  9 ng/ ml]) was significantly reduced by 92% with FOSAVANCE (70 mg/ 2800 IU) vs. alendronate-only (1% vs 13%, respectively).
http://www.emea.europa.eu/

Procentdelen af patienter med D - vitaminmangel (serum 25- hydroxyvitamin D ≤ 22, 5 nmol/ l [≤9 ng/ ml]) var signifikant reduceret med 92% med ADROVANCE (70 mg/ 2800 IE) versus alendronat alene (henholdsvis 1% versus 13%).
http://www.emea.europa.eu/

The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D < 22.5 nmol/ l [<  9 ng/ ml]) was significantly reduced by 92% with ADROVANCE (70 mg/ 2800 IU) vs. alendronate-only (1% vs 13%, respectively).
http://www.emea.europa.eu/

Efter 15 ugers behandling var de gennemsnitlige serum 25- hydroxyvitamin D niveauer signifikant højere (26%) i ADROVANCE (70 mg/ 2800 IE) gruppen (56 nmol/ l [23 ng/ ml]) end i gruppen med alendronat alene (46 nmol/ l [18, 2 ng/ ml]).
http://www.emea.europa.eu/

After 15 weeks of treatment, the mean serum 25-hydroxyvitamin D levels were significantly higher (26%) in the ADROVANCE (70 mg/ 2800 IU) group (56 nmol/ l [23 ng/ ml]) than in the alendronate-only group (46 nmol/ l [18.2 ng/ ml]).
http://www.emea.europa.eu/

D3-vitamin omdannes til 25-hydroxyvitamin D3 i leveren og lagres indtil der er brug for det.

Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver, and stored until needed.

ADROVANCE undersøgelser Effekten af den lavere dose af ADROVANCE (alendronat 70 mg/D3-vitamin 2800 IE) på D-vitamin status blev påvist i en 15 ugers multinational undersøgelse, der inkluderede 682 postmenopausale kvinder med osteoporose (serum 25-hydroxyvitamin D ved baseline:Gennemsnit, 56 nmol/l [ 22, 3 ng/ml ]; variationsbredde, 22, 5-225 nmol/l [ 9-90 ng/ml ]) .

ADROVANCE studies The effect of the lower dose of ADROVANCE (alendronate 70 mg/vitamin D3 2800 IU) on vitamin D status was demonstrated in a 15-week, multinational study that enrolled 682 osteoporotic post-menopausal women (serum 25-hydroxyvitamin D at baseline: mean, 56 nmol/l [ 22.3 ng/ml ]; range, 22.5-225 nmol/l [ 9-90 ng/ml ]) .

Biotransformation D3-vitamin metaboliseres hurtigt ved hydroxylering i leveren til 25-hydroxyvitamin D3 og metabolise -res efterfølgende i nyrerne til 1, 25-dihydroxyvitamin D3, som repræsenterer den biologisk aktive form.

Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3, and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3, which represents the biologically active form.

D3-vitamin fordeles hur -tigt til hovedsageligt leveren, hvor det metaboliseres til 25-hydroxyvitamin D3, den væsentligste op -lagringsform.

Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3, the major storage form.

I denne undersøgelse øgedes de gennemsnitlige 25-hydroxyvitamin D niveauer hos patienter med D -vitaminmangel ved baseline (25-hydroxyvitamin D, 22, 5 til 37, 5 nmol/l [ 9 til 15 ng/ml ]) fra 30 nmol/l (12, 1 ng/ml) til 40 nmol/l (15, 9 ng/ml) ved uge 15 i ADROVANCE (70 mg/2800 IE) -gruppen (n=75) og faldt fra 30 nmol/l (12, 0 ng/ml) ved baseline til 26 nmol/l (10, 4 ng/ml) ved uge 15 i gruppen med alendronat alene (n=70) .

In this study, mean 25-hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline (25-hydroxyvitamin D, 22.5 to 37.5 nmol/l [ 9 to 15 ng/ml ]) increased from 30 nmol/l (12.1 ng/ml) to 40 nmol/l (15.9 ng/ml) at week 15 in the ADROVANCE (70 mg/2800 IU) group (n=75) and decreased from 30 nmol/l (12.0 ng/ml) at baseline to 26 nmol/l (10.4 ng/ml) at week 15 in the alendronate-only group (n=70) .

Efter 15 ugers behandling var de gennemsnitlige serum 25-hydroxyvitamin D niveauer signifikant højere (26%) i ADROVANCE (70 mg/2800 IE) gruppen (56 nmol/l [ 23 ng/ml ]) end i gruppen med alendronat alene (46 nmol/l [ 18, 2 ng/ml ]) .

After 15 weeks of treatment, the mean serum 25-hydroxyvitamin D levels were significantly higher (26%) in the ADROVANCE (70 mg/2800 IU) group (56 nmol/l [ 23

Procentdelen af patienter med D -vitaminmangel (serum 25-hydroxyvitamin D 22, 5 nmol/l [ 9 ng/ml ]) var signifikant reduceret med 92% med ADROVANCE (70 mg/2800 IE) versus alendronat alene (henholdsvis 1% versus 13%) .

The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D 22.5 nmol/l [ 9 ng/ml ]) was significantly reduced by 92% with ADROVANCE (70 mg/2800 IU) vs. alendronate-only (1% vs 13%, respectively) .

Efter 24 ugers behandling var de gennemsnitlige serum 25-hydroxyvitamin D niveauer signifikant højere i D3 -vitamin 5600 gruppen (69 nmol/l [ 27, 6 ng/ml ] end i D3-vitamin 2800 gruppen (64 nmol/l [ 25, 5 ng/ml ].

After 24-weeks of treatment, the mean serum 25-hydroxyvitamin D levels were significantly higher in the Vitamin D3 5600 group (69 nmol/l [ 27.6 ng/ml ]) than in the Vitamin D3 2800 group (64 nmol/l [ 25.5 ng/ml ]) .

Procentdelen af patienter med D -vitaminmangel (serum 25-hydroxyvitamin D 22, 5 nmol/l [ 9 ng/ml ]) var signifikant reduceret med 92% med ADROVANCE (70 mg/2800 IE) versus alendronat alene (henholdsvis 1% versus 13%) .

32%, respectively) , through week 15.The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D 22.5 nmol/l [ 9 ng/ml ]) was significantly reduced by 92% with ADROVANCE (70 mg/2800 IU) vs. alendronate-only (1% vs 13%, respectively) .

Procentdelen af patienter med D-vitaminmangel (serum 25-hydroxyvitamin D 37, 5 nmol/l

17 ng/ml ]) than in the alendronate-only group (46 nmol/l [ 18.2 ng/ml ]) .

7 mg/2800 IE) gruppen (56 nmol/l [ 23 ng/ml ]) end i gruppen med alendronat alene (46 nmol/l [ 18, 2 ng/ml ]) .Procentdelen af patienter med D-vitaminmangel (serum 25-hydroxyvitamin D 37, 5 nmol/l [ 15 ng/ml ]) var signifikant reduceret med 62, 5% med ADROVANCE (70 mg/2800 IE) versus alendronat alene (henholdsvis 12% versus 32%) efter uge 15.

7 insufficiency (serum 25-hydroxyvitamin D 37.5 nmol/l [ 15 ng/ml ]) was significantly reduced by 62.5% with ADROVANCE (70 mg/2800 IU) vs. alendronate-only (12% vs.32%, respectively) , through week 15.

I denne undersøgelse øgedes de gennemsnitlige 25-hydroxyvitamin D niveauer hos patienter med D -vitaminmangel ved baseline (25-hydroxyvitamin D, 22, 5 til 37, 5 nmol/l [ 9 til 15 ng/ml ]) fra 30 nmol/l (12, 1 ng/ml) til 40 nmol/l (15, 9 ng/ml) ved uge 15 i FOSAVANCE (70 mg/2800 IE) gruppen (n=75) og faldt fra 30 nmol/l (12, 0 ng/ml) ved baseline til 26 nmol/l (10, 4 ng/ml) ved uge 15 i gruppen med alendronat alene (n=70) .

In this study, mean 25-hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline (25-hydroxyvitamin D, 22.5 to 37.5 nmol/l [ 9 to 15 ng/ml ]) increased from 30 nmol/l (12.1 ng/ml) to 40 nmol/l (15.9 ng/ml) at week 15 in the FOSAVANCE (70 mg/2800 IU) group (n=75) and decreased from 30 nmol/l (12.0 ng/ml) at baseline to 26 nmol/l (10.4 ng/ml) at week 15 in the alendronate-only group (n=70) .